BioAtla Investor Presentation Deck

AXL expression is associated poor prognosis in metastatic NSCLC Overall Survival (%) 100- 80- 60- 40- 0 bicatla 20 P=0.014 Low AXL -High AXL 40 Months 60 80 In a cohort of 98 patients with metastatic NSCLC, OS was significantly worse for those patients with high AXL expression by IHC Wu et al., J Cancer Res and Clin Oncol, 2017 Overall survival (%) No. at risk AXL low AXL high 100- 80- 60- 40- 20- 0+ 0 30 10 Median OS (95% CI), months = AXL low Undefined AXL high = 19 (14.4-23.7) 10 29 9 20 30 Follow-up (months) 24 5 17 3 -AXL low -AXL high HR=8.51 (p=0.004) 40 10 1 50 00 Lower overall survival (OS) in patients with early stage, surgically resected lung adenocarcinoma with high levels of tissue AXL Reproduced from de Miguel-Pérez D, et al. 2019 BioAtla| Overview 30

View entire presentation